716 related articles for article (PubMed ID: 29791829)
21. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
22. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
[TBL] [Abstract][Full Text] [Related]
23. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia.
Lee SK; Gosselin NH; Taylor J; Roberts MS; McKeever K; Shi J
J Clin Pharmacol; 2022 Jan; 62(1):87-98. PubMed ID: 34352114
[TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
27. Approach to Hypophosphatemic Rickets.
Ackah SA; Imel EA
J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
[TBL] [Abstract][Full Text] [Related]
28. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y; Kawanami D; Fukumoto S
Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
[TBL] [Abstract][Full Text] [Related]
29. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.
Zhang X; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Ito T; Vergeire M; Humphrey J; Glorieux FH; Portale AA; Insogna K; Carpenter TO; Peacock M
J Clin Pharmacol; 2016 Feb; 56(2):176-85. PubMed ID: 26073451
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Radiographic Global Impression of Change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH).
Lim R; Shailam R; Hulett R; Skrinar A; Nixon A; Williams A; Nixon M; Thacher TD
Bone; 2021 Jul; 148():115964. PubMed ID: 33878504
[TBL] [Abstract][Full Text] [Related]
32. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
Perwad F; Portale AA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
[No Abstract] [Full Text] [Related]
33. New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.
Marques JVO; Moreira CA; Borba VZC
Arch Endocrinol Metab; 2022 Nov; 66(5):658-665. PubMed ID: 36382755
[TBL] [Abstract][Full Text] [Related]
34. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
35. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
[TBL] [Abstract][Full Text] [Related]
36. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Balani S; Perwad F
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
[TBL] [Abstract][Full Text] [Related]
37. Burosumab treatment for fibrous dysplasia.
Gladding A; Szymczuk V; Auble BA; Boyce AM
Bone; 2021 Sep; 150():116004. PubMed ID: 33984553
[TBL] [Abstract][Full Text] [Related]
38. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
39. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
[TBL] [Abstract][Full Text] [Related]
40. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study).
Smith PS; Gottesman GS; Zhang F; Cook F; Ramirez B; Wenkert D; Wollberg V; Huskey M; Mumm S; Whyte MP
J Bone Miner Res; 2020 May; 35(5):920-931. PubMed ID: 31910300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]